PI polyamide

Patent metadata

Field	Value
Publication number	US-9522978-B2
Application number	US-201414773631-A
Country	US
Kind code	B2
Filing date	Mar 11, 2014
Priority date	Mar 11, 2013
Publication date	Dec 20, 2016
Grant date	Dec 20, 2016

Abstract

To provide a safe and stable medicine useful for prevention and treatment of prostate cancer.
A novel PI polyamide is acquired that recognizes and binds to a specific base sequence of an Oct1 gene binding sequence present in a transcriptional regulatory region (AR response region) of an ACSL3 gene and regulating the transcription activity of AR. This leads to the provision of an ACSL3 gene expression inhibitor and a preventive and/or therapeutic agent of prostate cancer containing the PI polyamide as an active ingredient.

First claim

The invention claimed is:

1. A pyrrole-imidazole polyamide binding to the whole or a part of a base sequence comprising SEQ ID NO:1, the pyrrole-imidazole polyamide being represented by any of the following Formulas 1 to 3:

2. An ACSL3 gene expression inhibitor containing a pyrrole-imidazole polyamide represented by any of the following Formulas 1 to 3:

as an active ingredient.

3. A preventive or therapeutic agent of prostate cancer containing the pyrrole-imidazole polyamide represented by any of the following Formulas 1 to 3:

as an active ingredient.

Assignees

• Univ Nihon

Inventors

• Obinata Daisuke
• Takahashi Satoru
• Fujiwara Kyoko
• Inoue Satoshi
• Takayama Kenichi

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07D403/14 Primary

  containing three or more hetero rings · CPC title

• C12Q2525/113

  incorporating modified backbone · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title